Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open- label, phase 3 trial - The Lancet
MHRA clarifies position on off-label Avastin - PharmaTimes
EU rules Avastin can be reimbursed for off-label use
File:Bevacizumab label 01.jpg - wikidoc
SecuringIndustry.com - WHO warns of fake cancer drugs in Uganda
Avastin approval for breast cancer pulled | CBC News
Avastin - FDA prescribing information, side effects and uses
Doctors appeal to prescribe Avastin off-label | Pharmafile
Avastin Lawsuits - Off-Label Use, Eye Infection, Blindness Risk
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology
France wants Avastin used in place of Lucentis - PMLiVE
ABPI chief exec backs Novartis legal challenge to off-label Avastin - PMLiVE
Avastin Injections Are Said to Cause Blindness - The New York Times
Avastin biosimilar may bring insurance benefits for Tecentriq < Pharma < 기사본문 - KBR
NHS wins legal fight with pharma over off-label Avastin - PMLiVE
Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year | NHS | The Guardian
Genentech: Statements | Genentech Statement on Counterfeit Drug Labeled as Avastin® (Bevacizumab) in the United States
More Medicare Musings: Why Lucentis is Worth the Price Tag - Eyedolatry
FDA Begins Process to Remove Breast Cancer Indication from Avastin Label - rgVision Magazine
Avastin - FDA prescribing information, side effects and uses
Immunotherapy Regimen Approved for Hepatocellular Carcinoma - MPR
EFPIA Files Complaint Against French Law Promoting Off-Label Avastin Use – Policy & Medicine
